UNSPSC 51271924: Propoxycaine hydrochloride

This classification denotes an anesthetic agent with the molecular formula C16H26N2O3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K490D39G46, chemically known as benzoic acid, 4-amino-2-propoxy-, 2-(diethylamino)ethyl ester, monohydrochloride but more generally known as propoxycaine hydrochloride, which bears US NIH Compound Identifier 11078. European Medicines Agency schedules Propoxycaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04089MIG.

UNSPSC 51271924 Propoxycaine hydrochloride is a Commodity code that captures state and local procurement of branded and generic local anesthetic pharmaceuticals supplied through cooperative purchasing vehicles and direct wholesaler relationships. State and local government actually buys propoxycaine and related injectable local anesthetics for use in medical facilities, dental clinics, surgical centers, and emergency departments operated by health departments, correctional facilities, and public hospital systems. The scope includes supply chain compliance with cGMP and DSCSA certification, NDC-level product specification, multiple authorized-wholesaler distribution networks, and pricing flexibility through flat-rate, net-price, or WAC-minus contract structures. Issuing bodies under this code include state departments of health and administration, county health systems, municipal hospitals, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) on January 20, 2026 to establish multiple contracts for generic and branded pharmaceuticals, including propoxycaine and similar local anesthetics, for distribution to participating state and local facilities in Minnesota, Oregon, and other member jurisdictions. The RFP closes March 26, 2026, with questions due February 18, 2026 and contract awards effective July 1, 2026. Products must be available in the marketplace by May 15, 2026 and distributed through three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Evaluation weights 75 percent to price competitiveness, 10 percent to fixed pricing, 5 percent each to EDI capability, administrative-fee compliance, and format adherence. Vendors must carry commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, with a two-year initial contract term and optional extensions at MMCAP's discretion.